

Supplemental Table 4. Analysis of exogenous Epo administration and LPFS by *Hsp70* family member mRNA.*

Marker/ Resection Stratum	Below Median† Marker Value			Above Median† Marker Value		
	Number of Patients		Log Rank P Value ‡	Number of Patients		Log Rank P Value ‡
	Epo	Placebo		Epo	Placebo	
<i>Hsp70_1a+1b</i>						
All Patients	31	31	0.69	29	32	0.68
Complete	15	15	0.84	15	14	0.45
Incomplete	7	6	0.68	4	8	0.48
No Resection	10	10	0.02	9	10	0.23
<i>Hsp70_2</i>						
All Patients	28	33	0.98	32	29	0.39
Complete	17	13	0.38	13	16	0.92
Incomplete	5	8	0.31	6	6	0.94
No Resection	7	12	0.05	12	7	0.46
<i>Hsp70_5</i>						
All Patients	31	29	0.85	27	33	0.34
Complete	14	14	0.81	14	14	0.35
Incomplete	7	6	0.98	4	8	0.25
No Resection	9	11	0.006	10	9	0.82
<i>Hsp70_6</i>						
All Patients	27	35	0.27	33	28	0.80
Complete	12	18	0.84	18	11	0.52
Incomplete	5	8	0.62	6	6	0.20
No Resection	10	10	0.05	9	10	0.20
<i>Hsp70_8</i>						
All Patients	31	31	0.88	29	32	0.51
Complete	15	15	0.34	15	14	0.81
Incomplete	7	6	0.89	4	8	0.09
No Resection	9	11	0.005	10	9	0.60
<i>Hsp70_9</i>						
All Patients	30	29	0.61	27	32	0.18
Complete	15	13	0.09	13	15	0.58
Incomplete	6	7	0.65	5	7	0.56
No Resection	9	10	0.005	9	9	0.29
<i>Hsp70_1L</i>						
All Patients	16	14	0.63	13	17	0.84
Complete	11	5	0.56	6	9	0.68
Incomplete	3	4	0.01	2	5	0.21
No Resection	4	4	0.10	3	4	0.40

* Stratification was above versus below/equal to the median.

† The median was calculated separately for all patients and within each resection stratum.

‡ The p value is based on the log rank test to compare differences in Kaplan Meier distributions in response to Epo versus placebo. **Groups with significant adverse effects of Epo are in bold.** The p value is two-sided.